From June 25 to 28, the 2024 China Medical and Health Industry Symbiosis Conference (17th MHIS) were grandly held. During the event, the selection results of the "2024 China Pharmaceutical · Brand List" were announced, with JumpCan Pharmaceutical's Pudilan Xiaoyan Oral Liquid and Xiao'er Chiqiao Qingre Granules (Tonpei) earning places on the list due to their outstanding brand reputation.
As a renowned annual gathering in the pharmaceutical and health industry, the MHIS brought together more than 5,000 industry elites, including government and association leaders, clinical and industry experts, representatives from top national and regional pharmacy chains, leading pharmaceutical manufacturers, hospital and retail terminals, renowned innovative pharmaceutical companies, technology platforms, and mainstream media representatives. The event served as a platform for sharing professional knowledge, discussing innovative development models, promoting resource connection and cooperation across the entire industry chain, and guiding continuous industry upgrading and innovation.
The China Pharmaceutical · Brand List is one of the most authoritative pharmaceutical rankings in China. Relying on MENET's scientific and objective terminal data system and a vast professional community, the list is compiled based on products' sales revenue and growth trends across three major terminal markets over the past three years, reflecting the final choices of clinicians and consumers. It objectively represents product excellence and distinguished brand quality.
Pudilan Xiaoyan Oral Liquid is a unique formulation product of JumpCan Pharmaceutical. As a star TCM for clearing heat, detoxifying, and relieving throat and oral discomfort, it held market shares of approximately 12% in Chinese urban public hospitals and 8% in retail pharmacies in the heat-clearing and detoxifying TCM market in 2023. It is highly praised by doctors, pharmacists, and consumers. The product has repeatedly won the "China Pharmacy Staff's Most Recommended Brand Award" and was listed on the "Clinical Value TCM Brand List." It has also been honored as the "Most Popular Star Product in Pharmacies", "Family Medication Recommended Product" and "Healthy China Top Ten Best-Selling Drug Brands." This year, it was also recognized as a "Best-Selling Brand in China's Pharmaceutical Retail Market" with continuously growing market reputation and increasing brand value.
Xiao'er Chiqiao Qingre Granules (Tonpei) is a leading pediatric cold medicine, an exclusive product included in the national medical insurance catalog. In 2023, it held market shares of approximately 45% in Chinese urban public hospitals and 39% in retail pharmacies in the pediatric cold TCM market, ranking among the top in both segments. It has been awarded honors such as "Healthy China · Most Recommended Children's Drug Brand by Parents", "Clinical Value TCM Brand List", "Most Recognized Pediatric Brand by Primary Care Doctors" and "China Pharmacy Staff's Most Recommended Brand Award." In March, it was named a "Potential Brand in China's Pharmaceutical Retail Market." This high-quality product safeguards children's health and has become a trusted children's medication brand among doctors, pharmacies, and parents.
The inclusion of Pudilan Xiaoyan Oral Liquid and Xiao'er Chiqiao Qingre Granules (Tonpei) in the China Pharmaceutical · Brand List once again demonstrates the market's high recognition of JumpCan Pharmaceutical's product brands. The company will continue to uphold its corporate mission of "Using Technology to Safeguard Health" and its quality philosophy of "Quality First", striving to develop more products with strong clinical efficacy, high technological content, and excellent brand reputation to promote public health. JumpCan Pharmaceuticalis committed to becoming a leading comprehensive pharmaceutical group trusted by patients.